Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
203.21
Industry P/E
--
Debt to Equity
0.57
ROE
-17.09 %
ROCE
61.69 %
Div. Yield
0 %
Book Value
0.65
EPS
7.49
CFO
$-356.83 Mln
EBITDA
$-366.34 Mln
Net Profit
$-427.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -61.19 | -17.75 | -62.58 | -99.08 | -96.38 | -89.51 | -69.68 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -99.29 | -73.98 | -94.57 | -68.07 | 33.11 | 9.37 | 7.93 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,700.36 | -- | 38.11 | |
| 71.71 | 7,308.19 | 52.48 | 23.56 | |
| 59.16 | 11,224.39 | 386.67 | 0.76 | |
| 8.13 | 9,322.72 | -- | -3.24 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the... treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Address: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 Read more
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
Headquarters
Tel Aviv
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Redhill Biopharma Ltd - ADR stood at $ 23 Mln as on 31-Dec-23
The share price of Redhill Biopharma Ltd - ADR is $2.41 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Redhill Biopharma Ltd - ADR has given a return of -96.38% in the last 3 years.
Redhill Biopharma Ltd - ADR has a market capitalisation of $ 4 Mln as on 24-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Redhill Biopharma Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Redhill Biopharma Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Redhill Biopharma Ltd - ADR.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Address: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921
The CEO & director of Mr. Dror Ben-Asher. is Redhill Biopharma Ltd - ADR, and CFO & Sr. VP is Mr. Dror Ben-Asher.
There is no promoter pledging in Redhill Biopharma Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Redhill Biopharma Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-103.24
|
|
Operating margin(%)
|
373.38
|
|
Net Margin(%)
|
367.19
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Redhill Biopharma Ltd - ADR was $-36 Mln.
$0.09
(
